Editorial

Insights & Research

Deep-dives, opinion, and science-led commentary on immuno-oncology, biomarkers, and precision medicine — from the ImmunoMark editorial team and guest contributors.

Featured

April 2026 · 13 min read

Best Immuno-Oncology Conferences to Attend in 2026

Top 10 Immuno-Oncology Conferences to Attend in 2026. Picking an immuno-oncology conference used to be simple when there were only a handful each year. Now, IO meetings pop…

Anwesha Mishra

Read Article →

Latest Articles

All

How to Validate an IO Biomarker in a Clinical Trial: Expert Guidance

How to Validate an IO Biomarker in a Clinical Trial: Expert Guidance You have a promising IO biomarker. You have…

Anwesha Mishra May 2026

All

Boston Biotech & Life Sciences Events 2026: Complete Guide

Boston Biotech & Life Sciences Events 2026: Your Complete Guide Boston has long been one of the world’s most important…

Anwesha Mishra Apr 2026

All

Tumor Mutational Burden (TMB): From Research to Clinical Reality

Tumor Mutational Burden: From Research to Clinical Reality Every few years, a biomarker arrives that genuinely changes how we think…

Anwesha Mishra Apr 2026

All

Speaker Spotlight Series: Pioneers Shaping IO Biomarker Science

Speaker Spotlight Series: Pioneers Shaping IO Biomarker Science ImmunoMark Summit | UK Edition 2026 | London ImmunoMark Summit is the…

Anwesha Mishra Apr 2026

All

FDA Companion Diagnostic Approval Process: A Step-by-Step Regulatory Guide

The FDA Companion Diagnostic Approval Process: A Regulatory Guide for Clinical Development and RA Teams For clinical development and regulatory…

Anwesha Mishra Apr 2026

All

Understanding PD-L1 as a Predictive Biomarker: Clinical Insights for Precision Oncology

Understanding PD-L1 as a Predictive Biomarker: Clinical Insights for Precision Oncology PD-L1 expression has become a cornerstone in cancer immunotherapy…

Anwesha Mishra Apr 2026

Join us for our Upcoming Editions

400+ senior leaders. Two streams. One agenda: advancing precision oncology.